Cargando…

Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine

Detalles Bibliográficos
Autores principales:	Wang, Mingwei, Wen, Wen, Zhou, Mengyun, Wang, Chunyi, Feng, Zhan-hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767906/ https://www.ncbi.nlm.nih.gov/pubmed/35063268 http://dx.doi.org/10.1016/j.amjcard.2021.12.007

Ejemplares similares

Incidence of Myocarditis after Messenger RNA Vaccine for COVID-19 in Young Male Recipients
por: Kato, Shingo, et al.
Publicado: (2022)

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
por: Le Vu, Stéphane, et al.
Publicado: (2022)

Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis
por: Xu, Wencheng, et al.
Publicado: (2022)

Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination—A nationwide study
por: Su, Wei-Ju, et al.
Publicado: (2023)

Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series
por: Murakami, Yoshiki, et al.
Publicado: (2021)

Overlapping Myocarditis and Postural Orthostatic Tachycardia Syndrome After COVID-19 Messenger RNA Vaccination: A Case Report
por: Sanada, Yuichi, et al.
Publicado: (2022)

A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients
por: Naveed, Zaeema, et al.
Publicado: (2023)

Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data
por: Lin, Yen-Ching, et al.
Publicado: (2023)

Explore the attitudes of children and adolescent parents towards the vaccination of COVID-19 in China
por: Wang, Lin, et al.
Publicado: (2022)

A meta-analysis of the association between calprotectin and the severity of COVID-19
por: Mao, Qin, et al.
Publicado: (2022)

Post-COVID-19 fatigue among COVID-19 in patients discharged from hospital: A meta-analysis
por: Ji, Guohua, et al.
Publicado: (2022)

Meta-analysis of post-traumatic stress disorder and COVID-19 in patients discharged
por: Chen, Chen, et al.
Publicado: (2022)

Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination
por: Kawano, Hiroaki, et al.
Publicado: (2022)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Food Safety Knowledge, Attitudes, and Self-Reported Practices Among Medical Staff in China Before, During and After the COVID-19 Pandemic
por: Luo, Lin, et al.
Publicado: (2021)

Multidrug-resistant infection in COVID-19 patients: A meta-analysis
por: Hu, Siqi, et al.
Publicado: (2023)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report
por: Fujii, Masayoshi, et al.
Publicado: (2023)

Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation
por: Lim, Yongwhan, et al.
Publicado: (2021)

Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study
por: Birabaharan, Morgan, et al.
Publicado: (2022)

The Dilemma of Masks During the COVID-19 Outbreak
por: Chen, Juan, et al.
Publicado: (2021)

Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

HIV and Messenger RNA (mRNA) Vaccine
por: Khalid, Khizer, et al.
Publicado: (2021)

Acute interstitial nephritis after messenger RNA-based vaccination
por: Czerlau, Cecilia, et al.
Publicado: (2021)

Sustained Myocarditis following Messenger RNA Vaccination against Coronavirus Disease 2019: Relation to Neutralizing Antibody and Amelioration by Low-Dose Booster Vaccination
por: Miyazaki, Koji, et al.
Publicado: (2023)

Myocarditis rare after COVID-19 mRNA vaccination
Publicado: (2021)

Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination
por: Frustaci, Andrea, et al.
Publicado: (2022)

Myocarditis after COVID‐19 mRNA vaccination in Australia
por: Varma, Suraj K, et al.
Publicado: (2022)

Olfactory dysfunction after COVID‐19: metanalysis reveals persistence in one-third of patients 6 months after initial infection
por: Hu, Siqi, et al.
Publicado: (2023)

Branch Retinal Vein Occlusion after Messenger RNA-Based COVID-19 Vaccine
por: Sugihara, Kazunobu, et al.
Publicado: (2022)

Medical emergency calls and calls for central nervous system symptoms during the COVID-19 outbreak in Hangzhou, China
por: Fu, Xinyan, et al.
Publicado: (2022)

Myocarditis after RNA-based vaccines for coronavirus.
por: Cordero, Alberto, et al.
Publicado: (2022)

Systemic Lupus Induced by Messenger RNA Vaccination
por: Voisin, Olivier, et al.
Publicado: (2022)

Imaging characteristics of myocarditis after mRNA‐based COVID‐19 vaccination: a meta‐analysis
por: Kato, Shingo, et al.
Publicado: (2022)

Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
Publicado: (2022)

Myocarditis and COVID-19 mRNA vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

COVID-19 mRNA Vaccine and Myocarditis
por: Singh, Balraj, et al.
Publicado: (2021)

Structural signatures of thermal adaptation of bacterial ribosomal RNA, transfer RNA, and messenger RNA
por: Jegousse, Clara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d16v00rist5h4p2iq5323tdeq9